Market crash throws up a rich deal for Cullinan
Trading well below cash hasn’t stopped Cullinan from extracting more from Otsuka, when a low-ball buyout might have been on the cards.
Six months on, Biohaven succumbs to Pfizer
Biohaven looks to have timed its exit well, giving investors more reason to cheer the $11.6bn buyout.
A bad day for Molecular Partners
Setbacks hit two of the Swiss biotech’s clinical-stage darpin projects in a single day.
